Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Routine molecular testing of non-small cell lung cancers in community settings

2012 ASCO Annual Meeting

Published: 4 Jun 2012

Views: 3979

Rating:

Save

Dr Thomas Zander - University Hospital Cologne, Germany

At a press conference during the ASCO 2012 Annual Meeting in Chicago, June 1st - June 4th, Dr Thomas Zander presented results from a multicenter study in Germany that reports it is feasible to routinely conduct high-quality molecular analysis of non-small cell lung cancers (NSCLC) in local community hospitals that are not affiliated with academic medical centers.

The study suggests that molecular testing can be made available to more patients, and in many cases, through hospitals closer to patients' homes.

Related Videos

Part 1: Why test?

Dr Elena Castro - Hospital Universitario 12 de Octubre, Madrid, Spain

Part 1: Why test? ( Dr Elena Castro - Hospital Universitario 12 de Octubre, Madrid, Spain )

Part 2: How to get biopsies for testing?

Dr Lynda Corrigan and Dr Stephen Finn

Part 2: How to get biopsies for testing? ( Dr Lynda Corrigan and Dr Stephen Finn )

BRCA1/BRCA2 germline mutations in patients with breast/ovarian cancer

Dr Wala Ben Kridis - Habib Bourguiba Hospital, Sfax, Tunisia

BRCA1/BRCA2 germline mutations in patients with breast/ovarian cancer ( Dr Wala Ben Kridis - Habib Bourguiba Hospital, Sfax, Tunisia )

Blood-based test may provide a convenient and effective option for CRC screening in the average-risk U.S. population

Dr Aasma Shaukat - NYU Grossman School of Medicine, New York, USA

Blood-based test may provide a convenient and effective option for CRC screening in the average-risk U.S. population ( Dr Aasma Shaukat - NYU Grossman School of Medicine, New York, USA )

Unlocking the potential of liquid biopsy applications in personalised care for older adults with cancer

Dr Yue Zhao - University Hospital of Cologne, Cologne, Germany

Unlocking the potential of liquid biopsy applications in personalised care for older adults with cancer ( Dr Yue Zhao - University Hospital of Cologne, Cologne, Germany )

New classification for identifying HR myeloma based on cytogenetic abnormalities

Dr Jill Corre - IUCT Oncopole, Toulouse, France

New classification for identifying HR myeloma based on cytogenetic abnormalities ( Dr Jill Corre - IUCT Oncopole, Toulouse, France )

Revolutionising myeloma treatment through immune profiling

Dr Romanos Sklavenitis-Pistofidis - Dana-Farber Cancer Institute, Boston, USA

Revolutionising myeloma treatment through immune profiling ( Dr Romanos Sklavenitis-Pistofidis - Dana-Farber Cancer Institute, Boston, USA )

Addressing the rise of multiple myeloma in Rwanda

Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda

Addressing the rise of multiple myeloma in Rwanda ( Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda )

Best practice in HRRm testing in patients with metastatic prostate cancer

Prof Martin Schostak, Dr Alexander Wyatt, Prof Charles Ryan and Dr Emmanuel Antonarakis

Best practice in HRRm testing in patients with metastatic prostate cancer ( Prof Martin Schostak, Dr Alexander Wyatt, Prof Charles Ryan and Dr Emmanuel Antonarakis )

More from ecancer